Mode
Text Size
Log in / Sign up
N/A N=71 Health Services Research

At Home Spirometry and Video Module Education for COPD Patients

COPD

Enrolled (actual)
71
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcome: Primary: Virtual Education Module Adherence — 17 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BREATHES Program (Other); BREATHES SpiroPD or Propeller Health (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Chicago
Primary completion
Jun 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Virtual Education Module Adherence
17
PRIMARY
Rate of SpiroPD Device Usage for At-Home COPD Self-Management
3
PRIMARY
Inhaler Technique
55; 17; 10
SECONDARY
Change in Self-Efficacy for Inhalers: 5 Point Likert Scale
47; 22; 49; 20
SECONDARY
Change in Symptom Burden
2.97; 2.28; 12.03; 12.72
SECONDARY
Change in Quality of Life: The Airway Questionnaire (AQ-20)
10.06; 11.70
SECONDARY
Use of Acute Care Services
19; 8; 17; 6; 1; 0

Summary

The central hypothesis is that patients hospitalized for COPD who subsequently complete the at-home BREATHES Program with V-TTG skill training and SpiroPD adherence support will retain increased medication knowledge, skill, self-efficacy, and adherence that otherwise decays substantially by 30 days post-discharge. To test this hypothesis, this study proposes the following specific aims: Aim 1: Determine the feasibility of, adherence to, and efficacy of at-home V-TTG for ongoing inhaler skill training. Hypothesis: Participants who complete both in-hospital and at-home V-TTG will have a significantly increased likelihood of demonstrating effective respiratory inhaler technique within 30 days after hospital discharge compared to in-hospital technique Aim 2. Determine the feasibility of, adherence to, and efficacy of at-home SpiroPD for COPD medication adherence support. Hypothesis: Participants' use of SpiroPD (PMD Healthcare) will significantly improve their COPD medication adherence.

Eligibility Criteria

Inclusion Criteria

  • Age 18 years and older
  • Physician-diagnosed COPD (prior to or during hospitalization)
  • Owns a wifi-enabled device (desktop, laptop, tablet, smart phone, etc.)
  • Discharged with a rescue and/or controller MDI (metered dose inhaler).

Exclusion Criteria

  • Currently in an intensive care unit
  • Physician declines to provide consent
  • Patient unable to provide consent (e.g., history of cognitive impairment, unable to understand English) or declines to provide consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03834350). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search